MedTrace Logo

Targeted Investigation of Microbiome Elimination

NCT05177328 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-11-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.

Conditions

Interventions

BIOLOGICAL

S. hominis A 9 Product

Commensal staph species, phosphate buffered saline, and glycerol.

DRUG

Placebo

Phosphate buffered saline and glycerol

Sponsors & Collaborators

  • Atopic Dermatitis Research Network

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Richard Gallo, M.D., Ph.D. · University of California, San Diego: Dermatology Clinical Trials Unit

  • Tissa Hata, M.D. · University of California, San Diego: Dermatology Clinical Trials Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-18
Primary Completion
2023-08-27
Completion
2023-10-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177328 on ClinicalTrials.gov